These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21429440)

  • 1. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Johansson S; Cullberg M; Eriksson UG; Elg M; Dunér K; Jensen E; Wollbratt M; Wåhlander K
    Int J Clin Pharmacol Ther; 2011 Apr; 49(4):258-67. PubMed ID: 21429440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Olsson SB; Rasmussen LH; Tveit A; Jensen E; Wessman P; Panfilov S; Wåhlander K
    Thromb Haemost; 2010 Mar; 103(3):604-12. PubMed ID: 20076850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
    Lip GY; Rasmussen LH; Olsson SB; Jensen E; Hamrén B; Eriksson UG; Wåhlander K
    Br J Clin Pharmacol; 2015 Dec; 80(6):1362-73. PubMed ID: 26174611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J; Mattsson C; Inghardt T; Elg M
    Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
    Lip GY; Rasmussen LH; Olsson SB; Zetterstrand S; Stahre C; Bylock A; Aunes-Jansson M; Eriksson U; Wåhlander K;
    Thromb Res; 2011 Feb; 127(2):91-9. PubMed ID: 21172721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.
    Sarich TC; Johansson S; Schützer KM; Wall U; Kessler E; Teng R; Eriksson UG
    J Clin Pharmacol; 2004 Apr; 44(4):388-93. PubMed ID: 15051746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs.
    Matsson EM; Palm JE; Eriksson UG; Bottner P; Lundahl A; Knutson L; Lennernäs H
    Drug Metab Dispos; 2011 Feb; 39(2):239-46. PubMed ID: 20978106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
    Wolzt M; Eriksson UG; Gouya G; Leuchten N; Kapiotis S; Elg M; Schützer KM; Zetterstrand S; Holmberg M; Wåhlander K
    Thromb Res; 2012 Apr; 129(4):e83-91. PubMed ID: 21925716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
    Lip GY; Rasmussen LH; Olsson SB; Jensen EC; Persson AL; Eriksson U; Wåhlander KF;
    Eur Heart J; 2009 Dec; 30(23):2897-907. PubMed ID: 19690349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
    Teng R; Sarich TC; Eriksson UG; Hamer JE; Gillette S; Schützer KM; Carlson GF; Kowey PR
    J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.
    Schützer KM; Svensson MK; Zetterstrand S; Eriksson UG; Wåhlander K
    Eur J Clin Pharmacol; 2010 Sep; 66(9):903-10. PubMed ID: 20535457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study.
    Walfridsson H; Johansson B; Englund A; Kennebäck G; Schwieler J; Kongstad O; Wåhlander K; Malm AR; Edvardsson N
    Clin Drug Investig; 2010; 30(7):461-71. PubMed ID: 20528001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
    Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
    Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.
    Ahrens I; Peter K; Lip GY; Bode C
    Discov Med; 2012 Jun; 13(73):445-50. PubMed ID: 22742650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
    Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
    Sarich TC; Schützer KM; Wollbratt M; Wall U; Kessler E; Eriksson UG
    J Clin Pharmacol; 2004 Aug; 44(8):935-41. PubMed ID: 15286098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.